FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL											
OMB Number:		3235-028									
l =											

Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

					2 10		· Nomo =	امت امم		dina C	Primah al			Ī	Dolot	ionobi	n of Donostin	na Darson(a) to	loouer	
Name and Address of Reporting Person*						2. Issuer Name and Ticker or Trading Symbol Marker Therapeutics, Inc. [MRKR]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
Eansor Norman David					warker rherapeutics, me. [wikiki]									X	Direc	tor 10% (Owner		
(Last) (First) (Middle) 3200 SOUTHWEST FREEWAY					3. Date of Earliest Transaction (Month/Day/Year) 05/09/2019											Office	er (give title w)	Other (specify below)		
SUITE 2240						4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable						
(Street)	ON T	ζ 7	77027										X Form filed by One Reporting Person Form filed by More than One Reporting Person							
(City)	(St	ate) (Zip)																	
		Tabl	e I - Nor	า-Deriv	ative	Se	curitie	s Acc	quired,	Dis	posed o	f, or	Bene	efici	ally C	Dwne	ed			
1. Title of Security (Instr. 3) 2. Transi Date (Month/L					2A. Deemed Execution Date of the property of t		n Date,	Transaction Dispo		Disposed	ecurities Acquired (A) osed Of (D) (Instr. 3, 4			4 and Secur Benef Owne Repor Trans		cially I Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
									Code	v	Amount (A) (D)		(A) or (D)			Price	action(s) 3 and 4)		(111511.4)	
Common Stock 05					05/09/2019				A		7,260	7,260 ⁽¹⁾ A		\$	0	7,260		D		
		Та	able II - D								sed of, onvertib				y Ow	ned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Da	Date,	4. Transaction Code (Instr. 8)		n of l		6. Date Exercisable an Expiration Date (Month/Day/Year)		е	7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4)			8. Pri Deriv Secui (Instr	ative dirity S	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)		Date Exercisal		Expiration Date	Title	or Nun of							

Explanation of Responses:

1. Represents the portion of the annual board retainer for each non-employee director payable in immediately vested, common stock under the Company's 2014 Omnibus Stock Ownership Plan, as amended and based on the closing price of \$5.51 per share, on the day immediately preceding the date of the Company's 2019 annual meeting.

/s/ Mark A. Catchur, as

Attorney-in-Fact for Norman 05/13/2019

David Eansor

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.